glp-1 obesity drug news today 2025-10-20 Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society GLP-1 Weight-Loss Drug Demonstration Begins

Specifically, we aim to determine whether yerba mat supplementation enhances GLP-1 and GIP secretion in vivo and to identify key bioactive metabolites responsible for these effects

The diabetes-induced reduction of neurogenesis in the hippocampal dentate implies a potential mechanism for diabetes-related cognitive decline

Represents a biopharmaceutic leap overcoming GI absorption barriers and first-pass metabolism for effective oral delivery

This included Matthias Tschp (figure 39), a German who completed a medical degree at Ludwig Maximilian University of Munich in 1993 and then worked as a clinician in neuroendocrinology before taking up a research fellowship at Eli Lilly Discovery Research Laboratories in 1999 to gain expertise in drug discovery and development

Many successful patients find that consuming 16-20 ounces of water upon waking helps establish a foundation for the day's hydration needs before the medication's effects fully take hold

Notably, the effect of tirzepatide as an anti-obesity medication is being investigated in the ongoing SURMOUNT clinical trial programme, in a similar manner to the assessment of semaglutide 2.4 mg for obesity in the Semaglutide Treatment Effect in People with obesity (STEP) programme [27]